anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present application relates to oligodendrocyte progenitor cell compositions. Compositions comprising populations of Oligodendrocyte Progenitor Cells (OPC) and methods of making and using the same are provided. In one aspect, a container is provided that contains a composition, wherein the composition comprises a cell population that contains a plurality of OPCs, and wherein the cell population comprises less than 15% of undesired cell types. In another aspect, the population of cells comprises less than 15% of cells of the undesired epithelial lineage. In another aspect, the population of cells comprises less than 2% K7 positive cells. In one aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells capable of forming less than 1 epithelial cyst per 100,000 cells in a cyst test is provided. Another aspect of the present disclosure is a container comprising a composition, wherein the composition comprising a plurality of oligodendrocyte progenitor cells is useful for treating stroke, spinal cord injury, and multiple sclerosis.
Subjects with MPM will undergo surgical mediastinal lymph node biopsy (cervical mediastinoscopy) and simultaneous surgical biopsy of the pleural tumor by thoracoscopy, at which time tumor tissue (at least 2 g) and peripheral blood will be collected for the study. These procedures are performed as standard of care in the treatment of these subjects. The subject will be randomized. Three days to three weeks after the biopsy, subjects will be randomly treated with either MEDI-4736 (15 mg/kg once intravenously) or MEDI-4736 (1500 mg once intravenously) plus tremelimumab (75 mg once intravenously) or a control group in a randomized controlled study design. There will be two treatment arms (MEDI4736 only and combination MEDI4736+tremelimumab) and one untreated arm (control). Randomization, stratified by receiving previous chemotherapy or not, will be performed and will help to minimize patient selection biases between three arms. Subjects under 30 kg will be treated with weight-based dosing for both MEDI4736 and Tremelimumab combination therapy. These patients are excluded from fixed based dosing to limit endotoxin exposure from the drug preparations. One to six weeks after the infusion, subjects will undergo resectional surgery, including extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), at which time the tumor will be removed (typically 200-1000 g) and obtained for study. Four patients that do not undergo treatment with MEDI-4736 or tremelimumab will be included as controls. Blood will be obtained after the induction of general anesthesia for both the thoracoscopy procedure and the EPP or P/D resectional procedure, as is routinely done in these procedures. The sixth rib will be obtained at the time of the resection. After the removal of the tumor, standard protocol includes intraoperative heated chemotherapy using a lavage of intracavitary cisplatin in the presence of conserved renal function (Sugarbaker et al., 2013, 2014; Richards et al., 2006).
Aim: The matrix metalloproteinases (MMPs) inhibit tissue inhibitors of metalloproteinases (TIMPs), playing a notable role in various biological processes, and mutations in TIMP2 genes impact a variety of urinary cancers. In this study, we analyze and evaluate the potential involvement of the TIMP2 418 G/C and MMP gene polymorphism in the etiology of urinary cancer. Methodology: For suitable case-control studies, a literature search was undertaken from various database sources such as PubMed, EMBASE, and Google Scholar. Incorporated into the analysis were case-control or cohort studies that documented the correlation between TIMP2 418 G/C and urological cancers. MetaGenyo served as the tool for conducting the meta-analysis, employing a fixed-effects model. The collective odds ratios, along with their corresponding 95% confidence intervals, were calculated and presented to assess the robustness of the observed associations. Results: A total of seven studies involving controls and cases out of recorded 1265 controls and 1154 cases were analyzed to ascertain the significant association of the TIMP2 gene with urologic cancer. No statistically significant correlation was observed between allelic, recessive, dominant, and overdominant models for the genetic variant under investigation. A 95% confidence interval (CI) and odds ratio (OR) were computed for each model, considering p-values <0.05. The OR and 95% CI for the allelic model were 0.99 and 0.77-1.27, respectively, whereas the respective values were 1.00 and 0.76-1.32 for the recessive model. In the dominant contrast model, OR and 95% CI were 1.09 and 0.62-1.90, while the same were 0.93 and 0.77-1.12 for the overdominant model. A funnel plot was used to reanalyze and detect the results as statically satisfactory. Conclusions: As a result of the data obtained, the TIMP2 gene polymorphism does not correlate statistically with cancer risk. The significance of this finding can only be confirmed using a large population, extensive epidemiological research, a comprehensive survey, and a better understanding of the molecular pathways associated.
Conductive cardiac patches can rebuild the electroactive microenvironment for the infarcted myocardium but their repair effects benefit by carried seed cells or drugs. The key to success is the effective integration of electrical stimulation with the microenvironment created by conductive cardiac patches. Besides, due to the concerns in a high re-admission ratio of heart patients, a remote medicine device will underpin the successful repair. Herein, we report a miniature self-powered biomimetic trinity triboelectric nanogenerator with a unique double-spacer structure that unifies energy harvesting, therapeutics, and diagnosis in one cardiac patch. Trinity triboelectric nanogenerator conductive cardiac patches improve the electroactivity of the infarcted heart and can also wirelessly monitor electrocardiosignal to a mobile device for diagnosis. RNA sequencing analysis from rat hearts reveals that this trinity cardiac patches mainly regulates cardiac muscle contraction-, energy metabolism-, and vascular regulation-related mRNA expressions in vivo. The research is spawning a device that truly integrates an electrical stimulation of a functional heart patch and self-powered e-care remote diagnostic sensor.
Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.
The present invention relates to dye compounds represented by [ formula I ] and [ formula II ] described in the specification. The dye compound of the present invention has significantly improved quantum efficiency and emits strong fluorescence compared to the existing cyanine dyes. Due to these advantages, the dye compound of the present invention can be applied in various fields, for example, as a probe for various biological systems in which optical imaging is required. In particular, the dye compounds of the present invention are useful as chromosome tracers capable of labeling and tracking mitochondria. Thus, the dye compounds of the present invention can be used to enable quantitative imaging of mitochondria in living tissues or cells. In addition, the dye compound of the present invention can be used as a pH probe for detecting the pH of living cells.
Unlike acute pulmonary embolism (PE), the resolution of thrombi is ineffective in chronic thromboembolic pulmonary hypertension (CTEPH), leading to reorganisation and fibrotic changes within the pulmonary arteries. The authors report the case of a man in his 60s with polycythemia vera, under warfarin, following an acute PE. He was admitted a year later with right heart failure and haemodynamic instability. Acute over chronic PE caused this severe presentation, confirmed by right heart catheterisation and pulmonary scintigraphy. The challenging diagnosis and management involved transfer to a centre specialised in pulmonary vascular disease. Normalisation of functional and haemodynamic parameters, sustained in 10-year follow-up, was achieved with anticoagulation and triple therapy with prostanoids as a bridge to pulmonary thromboendarterectomy. Targeted medical therapy, not standard at that time, was crucial to recovering conditions for transfer. An individualised approach, integrating multidisciplinary pulmonary hypertension expertise, provides the basis for the best care for CTEPH.
Many cocaine dependent individuals are also dependent on alcohol. Such individuals respond poorly to existing treatments and have received little research attention in the past. Naltrexone and disulfiram are medications currently approved for treating alcohol dependence. These two medications have different mechanisms of action in the body. In combination they might be effective in treating individuals dually diagnosed with cocaine and alcohol dependence. The purpose of this study is to determine whether the combination of naltrexone and disulfiram is useful in decreasing alcohol cravings in individuals who are dependent on both cocaine and alcohol.

Participants in this 5-year, double-blind study will be randomly assigned to receive disulfiram, naltrexone, both, or placebo. Treatment will occur for a 3-month period, after which alcohol, cocaine use, and other biopsychosocial measures will be assessed at Months 6 and 9.
No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
BACKGROUND: Numerous conditions may lead to gastrointestinal bleeding (GIB). Compared with common causes, hemosuccus pancreaticus (HP) is a scarce and potentially life-threatening condition.
CASE PRESENTATION: We report the case of a 45-year-old female patient who suffered from hematemesis and subsequent hemorrhagic shock. In repeat esophagogastroduodenoscopies, bleeding from the major duodenal papilla was detected. To stop the acute bleeding, an ERCP was performed, and a plastic stent was inserted into the pancreatic duct (PD). Subsequently, MR and CT scans demonstrated a pseudoaneurysm of the splenic artery (SA) with a fistula to the PD. An interventional therapy approach failed due to a highly twisted course of the SA. Thus, the patient underwent surgery with ligation of the SA. The stent from the PD was removed postoperatively, and the patient recovered well. A histological examination of the SA revealed fibromuscular dysplasia. A lifelong ASA therapy was prescribed, and the patient was discharged on the 14th postoperative day in good condition.
CONCLUSION: The diagnosis and treatment of HP might be impeded due to its multiple causes, ambiguous symptoms, and challenging diagnostic verification. Being a potentially life-threatening condition, the knowledge of this rare entity and the provision of multidisciplinary and multimodal therapy are mandatory for the successful treatment of patients with obscure GIB and proven HP.
Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if \<= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If \>= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
The present invention relates to compositions and methods for inhibiting plaque. In particular, this invention relates to oral compositions comprising: (a) a safe and effective amount of a carboxy-substituted polymer active agent having the formula  or the salts thereof, wherein R is a C1-C8 alkyl group, n is in the range of from 0 to about 2,000, m is in the range of from about 10 to about 2,000, and p is in the range of from about 1 to about 10; and (b) a pharmaceutically acceptable carrier. These compositions inhibit plaque without staining the tooth surfaces which are contacted with the composition. This invention also relates to a method of inhibiting plaque on tooth surfaces in the oral cavity. This method involves applying a safe and effective amount of the carboxy-substituted polymer active agent to the oral cavity. Such an application is typically made by applying the above-described oral compositions containing the carboxy-substituted polymer to the tooth surface. The application does not stain the teeth on which it is made.
Studies on the muscular-deep fascial system which connects the upper eyelid, brow, and glabella, are lacking. This study aimed to explore the fine anatomy of the muscular-deep fascial system in the region between the eyebrow and the superior orbital margin. We included eight formalin-phenol-embalmed cadavers (16 sides of specimens), and categorized them into anatomical dissections and histological sections. Five cadavers (10 sides) were dissected for gross anatomical observation, whereas all soft tissues of the other three cadavers (6 sides) were dissected for tissue sectioning and histological analysis. Three tissue blocks and 16 strips in each block were trimmed, numbered, and sliced into these specimens. Hematoxylin-Eosin and Masson's Trichrome staining were performed. In the region between the eyebrow and the superior orbital margin, the frontalis was covered by the orbicularis oculi. Fibers of the frontalis muscle penetrated into the orbicularis oculi muscle bundles, and crosslinked around the eyebrow level. Both the frontalis and the orbicularis oculi were attached to the thickened multilayered deep fascia in this region, which could be regarded as the muscular-deep fascial system. The muscular-deep fascial system connects the frontalis deep fascia and deep forehead compartments down to the orbicularis-supporting ligament. The precise anatomy of the muscular-deep fascial system in the region between the eyebrow and the superior orbital margin may provide a valuable reference for soft-tissue fixation and suspension in facial surgery.
BACKGROUND AND OBJECTIVES: The Kaiser Permanente Neonatal Early-Onset Sepsis (EOS) Calculator has been an effective tool for risk stratification to safely reduce newborn antibiotic exposure. The calculator was derived from data on infants born between 1993 and 2007. Since that time, US obstetric practice has adopted universal antepartum screening for group B Streptococcus and intrapartum antibiotic prophylaxis guidance has changed. Our objective was to update the EOS calculator using a contemporary birth cohort and determine the effect of these changes on EOS case ascertainment and antibiotic recommendations.
METHODS: The study included infants born at ≥35 weeks' gestation at 14 hospitals between January 2010 and December 2020 (n = 412 595 infants, EOS cases = 113). Model coefficients were re-estimated and the point estimates of the likelihood ratios for clinical status used to calculate the posterior probability of EOS. We compared the number of EOS cases correctly identified by each model (sensitivity) and the proportion of infants for whom empirical antibiotics are recommended.
RESULTS: The original model had a sensitivity of 0.76 (95% confidence interval 0.63-0.85), while the updated model had a sensitivity of 0.80 (95% confidence interval 0.68-0.89), P = .15. The recommended empirical antibiotic use was 3.5% with the original model and 3.7% with the updated model, P < .0001. For each additional case identified by the updated model, an additional 158 infants would be treated with antibiotics.
CONCLUSIONS: Both the original and updated EOS calculators are effective tools for quantifying EOS risk among infants born at ≥35 weeks' gestation.
The present invention relates to a MASH score for diagnosis of nonalcoholic steatohepatitis and, more specifically, to a score obtained by combining clinical findings, blood tests, and MRI results for patients to diagnose nonalcoholic steatohepatitis in all nonalcoholic fatty liver diseases. The prevalence rate of nonalcoholic fatty liver disease is increasing worldwide, and it is reported that about 30% of the total population in Korea also has nonalcoholic fatty liver disease. People with nonalcoholic fatty liver disease are known to have an increased overall mortality and mortality from liver disease. About 75% of patients with all nonalcoholic fatty liver disease have a good prognosis with simple fatty liver disease, but about 25% of patients with steatohepatitis have a poor prognosis. However, to diagnose steatohepatitis, it is necessary to observe hepatocyte ballooning through liver biopsy. However, biopsy is expensive, requires hospitalization, and involves the risk of side effects such as bleeding/infection, and thus there is a limit to proceeding in all patients. Therefore, the present invention provides a MASH score obtained by combining clinical findings, blood tests, and MRI results for patients to diagnose nonalcoholic steatohepatitis in all nonalcoholic fatty liver diseases. A method for providing information for diagnosis of MASH comprises a step of calculating a MASH score by putting obtained indexes to formula 1.
This is a randomized (participants are assigned to treatment groups by chance), double-blind (participants and study personnel know what study agents are given), placebo-controlled (a placebo is a treatment identical in appearance to CNTO 1959 but does not contain active drug), single-dose study. The study will include 24 participants: 4 groups of at least 6 participants each. If it is decided that additional data are needed to define the safety and tolerability of CNTO 1959, an additional group may be enrolled. A given dose level may be repeated in newly enrolled participants, or a lower or intermediate dose may be administered based on preliminary data. The total duration of participation will be approximately 30 weeks, which includes a screening period of up to 6 weeks before the administration of study agent. Participant safety will be monitored. Ascending doses of 10, 30, 100, and 300 mg dose of CNTO 1959 and placebo will be administered as single SC injections; however, 2 SC injections may be required for the 300 mg dose level. Dosing will be performed for 24 weeks.
A substantially pure benzoic acid ester of a mixture of alcohols. The mixture of alcohols consists essentially of (A) at least one C12 or C14 primary alcohol and (B) at least one C13 or C15 primary alcohol. The weight ratio of the even carbon number alcohols (A) to the odd carbon number alcohols (B) is from about 0.25:1 to about 4:1, preferably from about 0.5:1 to about 3:1. At least 70% by weight of each alcohol is linear and substantially all of the remainder of each alcohol is branched at the two carbon position. The compositions of this invention have unique properties in that they are substantially non-greasy, lack oiliness and greasiness, have low cloud points and pour points, have a bland odor, low toxicity, and are stable. The properties make such compositions useful as a vehicle or carrier, emollient or solubilizer for toiletry and cosmetic formulations, e.g., hair cream, hand cleaner, bath oil, suntan oil, brilliantine, anti-perspirants, perfumes and colognes, cold creams, electric pre-shave, eye and throat oil, fingernail polish, topical pharmaceutical ointments, lipsticks, stick rouge, skin lotions and creams, skin moisturizers, cleansing creams and after bath splash and lotions.
Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
ALDARA Cream should be used as directed by a physician [see Dosage and Administration (2)]. ALDARA Cream is for external use only. Contact with the eyes, lips, and nostrils should be avoided [see Indications and Usage (1)and Dosage and Administration (2)]. The treatment area should not be bandaged or otherwise occluded. Partially used packets should be discarded and not reused. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy. 

It is recommended that patients wash their hands before and after applying ALDARA Cream.
Provided are a method for preparing oligodendrocytes and use. According to the solution provided, the major steps of oligodendrocyte differentiation is replayed in a time significantly shorter than 75-95 days which are required for previous solutions. The cannabinoid receptor agonist WIN55212-2 is used to induce NSC differentiation, promoting OLIG2 + OPC induction. WIN-derived OLIG2 + progenitor cells differentiate into PDGFRα + OPCs, which have high mobility and can further differentiate into mature OLs with a powerful myelination ability. When WIN-derived OPCs are transplanted to lesions, the mobility of mice with spinal cord injury (SCI) begins to improve significantly the second week after the transplantation. The results of immunostaining show that WIN-derived OPCs can differentiate into mature OLs, causing myelination of damaged axons.
<P>PROBLEM TO BE SOLVED: To improve convenience in the case of changing the patient attribute information of inspection data related with a sample.  <P>SOLUTION: An attribute information updating terminal 60 transmits a patient attribute information acquisition request to an information processor (electronic medical record server 30, medical image server 50) for managing patient attribute information, and obtains patient attribute information corresponding to the acquisition request. The attribute information update terminal 60 generates an instruction (update target HL7 reference sample inspection result data and overwrite instruction) to update the patient attribute information of inspection data stored and managed by an inspection data management server 70 based on the patient attribute information. The attribute information update terminal 60 transmits the update target HL7 reference sample inspection result data and the overwrite instruction to the inspection data management server 70. The inspection data management server 70 updates the original HL7 reference sample inspection result data based on the update target HL7 reference sample inspection result data and the overwrite instruction.  <P>COPYRIGHT: (C)2010,JPO&INPIT